Drug Profile


Alternative Names: CM-082; X-82

Latest Information Update: 17 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tyrogenex
  • Developer AnewPharma; Tyrogenex; Washington University School of Medicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Renal cell carcinoma
  • Phase II Age-related macular degeneration
  • Phase I/II Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 08 Jun 2017 Adverse events data from a phase I/II trial in Age-related macular degeneration released by Tyrogenex
  • 02 Jun 2017 Phase-II/III clinical trials in Renal cell carcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (PO, Tablet)
  • 02 Jun 2017 Preliminary efficacy and adverse events data from a phase I trial in Renal cell carcinoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top